Page 56 - GALENIKA MEDICAL JOURNAL

hemodiafiltration (CVVHDF). The dosage of antibiotics in these patients is specific and adjusted to the individual patient and
his kidney function.

Peritoneal dialysis patients in the terminal phase of chronic kidney failure are at risk of developing peritonitis. The
guides describe which antibiotics are used to start the treatment of peritonitis and how the antibiotics are then adjusted,
according to the causative agent, after the dialysate culture is obtained. Treatment of peritonitis is mainly by intraperitoneal
administration of antibiotics, but it is also possible with oral or parenteral antibiotics, i.e. their combination. The guidelines
describe the initial and maintenance doses of antibiotics and antifungals. If treatment is not started on time, the dialysis
method may be compromised and the patient may die. If fungi are isolated by culture, the treatment of the patient with
peritoneal dialysis is stopped and the dialysis catheter is removed, and the treatment is continued with the administration
of antibiotics intravenously.

Keywords: chronic kidney failure, hemodialysis, peritoneal dialysis, antibiotics

Literatura 13. KDIGO CKD Work Group: Kidney disease: Improving global outcomes
(KDIGO) CKD work group. KDIGO 2012 clinical practice quideline for
the evaluation and management of chronic kidney disease. Kidney Int
1. Al Himali N, Al Suleimani YM, Al-Zakwani I, Abdelrahman AM. Antibiotics Soppl 2013;3:1-150.
utilization patterns and dosage appropriateness among patients 14. Vrcelj-Jovanović S, Radonjić V, Đurović D, Đukić Lj (urednici). Beograd:
receiving hemodialysis. Saudi Pharm J. 2022 Jul;30(7):971-8. Agencija za lekove i medicinska sredstva Srbije 2017. Dostupno
2. Djukanovic Lj (urednik poglavlja). Izbor i doze lekova u hronicnim na: https.//www.alims.gov.rs/ciril/ files/2017/04/NRL_2017_fin.pdf .
bolestima bubrega. U:Djukanovic Lj, Dimkovic N, Jovanovic D, Lezaic Pristupljeno 13 maja, 2019.
V, Naumovic R, Simic-Ogrizovic S (urednici): Bolesti bubrega (drugo 15. Awdishu L, Bouchard J. How to optimize drug delivery in renal
dopunjeno izdanje), Akademska misao, Beograd; 2021: 668-83. replacement therapy. Semin Dial. 2011 Mar-Apr;24(2):176-82.
(Serbian)
16. Thongsanit S, Pietruszka M, Shull S, Gast C. UW Health Renal Function-
3. Cervelli MJ, Russ GR. Principles of Drug Therapy, Dosing, and Based Dose Adjusments – Adult – Inpatient/Ambulatory Clinical Practice
Prescribing in Chronic Kidney Disease and Renal Replacement Therapy. Guideline. Madison, WI: University of Wisconsin Hospitals and Clinics
In: Johnson RJ, Feehally J, Floege J (editors). Comprehensive Clinical Avilable at: https:// www. uwhealth.org/ cckm/cpg/medications/
Nephrology, 5th edition. Philadelphia, PA: Elsevier Saunders; 2015.885- Renal-Function-Based-Dose-Adjusments---Adult---Inpatient.
904. Ambulatiry-17.06.27.pdf. Accessed May 20, 2020.
4. Olyaei AJ, Foster TA and Lerma EV. Drug dosing in chronic kidney 17. Hoff BM, Maker JH, Dager WE, Heintz BH. Antibiotic Dosing for
disease. In: Turne N, Lameire N, Goldsmith DJ, Winearls CG, Critically Ill Adult Patients Receiving Intermittent Hemodialysis,
Himmelfarb J, and Remuzzi G (editors). Oxford University Press; 2016. Prolonged Intermittent Renal Replacement Therapy, and Continuous
2911-8. Renal Replacement Therapy: An Update. Ann Pharmacother. 2020
5. Matzke GR, Keller F. Drug Dosing Considerations in Patients with Acute Jan;54(1):43-55.
Kidney Injury and Chronic Kidney Disease. In: Skorecki K, Chertow 18. Li PK, Chow KM, Cho Y, Fan S, Figueiredo AE, Harris T, et al. ISPD
GM, Marsden PA, Taal MW, Yu ASL (editors). Brenner and Rector’s The peritonitis guideline recommendations: 2022 update on prevention and
Kidney, 10th edition. Philadelphia, PA: Elsevier Saunders; 2016. 2034-55. treatment. Perit Dial Int. 2022 Mar;42(2):110-53.
6. Olyaei AJ, Steffl JL. A quantitative approach to drug dosing in chronic 19. Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, et al;
kidney disease. Blood Purif. 2011;31(1-3):138-45. International Society for Peritoneal Dialysis. Peritoneal dialysis-related
7. Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt infections recommendations: 2010 update. Perit Dial Int. 2010 Jul-
KU, et al. Drug dosing consideration in patients with acute and chronic Aug;30(4):393-423.
kidney disease-a clinical update from Kidney Disease: Improving Global 20. Li PK, Szeto CC, Piraino B, de Arteaga J, Fan S, Figueiredo AE, et al.
Outcomes (KDIGO). Kidney Int. 2011 Dec;80(11):1122-37. ISPD Peritonitis Recommendations: 2016 Update on Prevention and
8. Djukanovic Lj, Ležaić V. Ispitivanje bolesnika sa oboljenjima bubrega. Treatment. Perit Dial Int. 2016 Sep 10;36(5):481-508.
U:Djukanovic Lj, Dimkovic N, Jovanovic D, Lezaic V, Naumovic R, Simic- 21. de Vin F, Rutherford P, Faict D. Intraperitoneal administration of drugs
Ogrizovic S (urednici): Bolesti bubrega (drugo dopunjeno izdanje), in peritoneal dialysis patients: a review of compatibility and guidance
Akademska misao, Beograd; 2021: 19-52. (Serbian) for clinical use. Perit Dial Int. 2009 Jan-Feb;29(1):5-15.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum
creatinine. Nephron. 1976;16(1):31-41.
10. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more Konflikt interesa: Nema
accurate method to estimate glomerular filtration rate from serum
creatinine: a new prediction equation. Modification of Diet in Renal Primljeno: 27. 12. 2022.
Disease Study Group. Ann Intern Med. 1999 Mar 16;130(6):461-70.
Prihvaćeno: 17. 01. 2023.
11. Elseviers MM, Verpooten GA, De Broe ME, De Backer GG. Interpretation Onlajn: 01. 03. 2023.
of creatinine clearance. Lancet. 1987 Feb 21;1(8530):457.
12. Đukanović Lj. Ispitivanje bolesnika sa oboljenjima bubrega. U:
Đukanović Lj i Oštrić V (urednici). Bolesti bubrega. Beograd: Zavod za
udžbenike i nastavna sredstva;1999, 1-38. (Serbian)

54 DOI: 10.5937/Galmed2305047J